NCT05608681 - A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE). | Biotech Hunter

Enrollment

117

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Eosinophilic Esophagitis

Interventions

DRUG

EP-104GI

Extended-release fluticasone propionate \[FP\] for injectable suspension for gastrointestinal administration, Powder suspended in vehicle

OTHER

Matching vehicle control

A sterile liquid containing sterile water and excipients necessary to prepare a uniform suspension of the powder.

Trial Locations (7)

RECRUITING

Amsterdam UMC, Amsterdam

RECRUITING

Eastern Health Box Hill, Box Hill

RECRUITING

Campbelltown Private Hospital, Sydney

RECRUITING

Princess Alexandra Hospital, Brisbane

RECRUITING

Royal Adelaide Hospital, Adelaide

RECRUITING

McGill University Health Center, Montreal

RECRUITING

G.I. Research Institute, Vancouver